CGx Testing

Community Protection through Non-Invasive Screening

AlcoaOne has developed a specialized CGx test designed to empower individuals who may be facing significant health risks. This test uncovers whether patients have genetic predispositions to common and challenging to treat cancers, such as Breast, Prostate, Pancreatic, and Ovarian. Our test provides crucial insights that can help clinicians personalize treatment plans and accurately assess risk levels. It plays a vital role in identifying genetic variations, that make patients more susceptible to certain hard-to-diagnose and treat cancers.

Pinpointing Risks for Early Intervention

Moreover, the test helps protect patients from the complications of polypharmacy - the concurrent use of multiple medications. By providing a detailed understanding of how a patient might react to a wide range of medications, healthcare providers can minimize the risk of adverse drug reactions and identify potential drug-drug interactions or adverse effects based on a patient's genetics, thus significantly enhancing the safety of prescribed treatments.

Family Planning

AlcoaOne's CGx test analyzes patients' DNA to pinpoint genetic and hereditary risks. This crucial information allows doctors to formulate early assessment plans at no cost to the patient. AlcoaOne's approach targets a broad range of specific gene variants, including BRCA1/BRCA2, which can indicate various types of cancers. When combined with a patient's medical history, this gives an in-depth understanding of a patient's risk level for the aforementioned cancers.